These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

325 related articles for article (PubMed ID: 25183962)

  • 21. Cytosolic tryparedoxin of Leishmania donovani modulates host immune response in visceral leishmaniasis.
    Suman SS; Amit A; Singh KP; Gupta P; Equbal A; Kumari A; Topno RK; Ravidas V; Pandey K; Bimal S; Das P; Ali V
    Cytokine; 2018 Aug; 108():1-8. PubMed ID: 29554571
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A Leishmania amastigote-specific hypothetical protein evaluated as recombinant protein plus Th1 adjuvant or DNA plasmid-based vaccine to protect against visceral leishmaniasis.
    Oliveira-da-Silva JA; Machado AS; Ramos FF; Tavares GSV; Lage DP; Mendonça DVC; Pereira IAG; Santos TTO; Martins VT; Carvalho LM; Freitas CS; Ludolf F; Reis TAR; Bandeira RS; Silva AM; Costa LE; Oliveira JS; Duarte MC; Roatt BM; Teixeira AL; Coelho EAF
    Cell Immunol; 2020 Oct; 356():104194. PubMed ID: 32827943
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Combined Immune Therapy for the Treatment of Visceral Leishmaniasis.
    Faleiro RJ; Kumar R; Bunn PT; Singh N; Chauhan SB; Sheel M; Amante FH; Montes de Oca M; Edwards CL; Ng SS; Best SE; Haque A; Beattie L; Hafner LM; Sacks D; Nylen S; Sundar S; Engwerda CR
    PLoS Negl Trop Dis; 2016 Feb; 10(2):e0004415. PubMed ID: 26872334
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Understanding Resistance vs. Susceptibility in Visceral Leishmaniasis Using Mouse Models of
    Pérez-Cabezas B; Cecílio P; Gaspar TB; Gärtner F; Vasconcellos R; Cordeiro-da-Silva A
    Front Cell Infect Microbiol; 2019; 9():30. PubMed ID: 30881923
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Recovery of antigen-specific T cell responses from dogs infected with Leishmania (L.) infantum by use of vaccine associated TLR-agonist adjuvant.
    Schaut RG; Grinnage-Pulley TL; Esch KJ; Toepp AJ; Duthie MS; Howard RF; Reed SG; Petersen CA
    Vaccine; 2016 Oct; 34(44):5225-5234. PubMed ID: 27665354
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Identification of Leishmania infantum chagasi proteins in urine of patients with visceral leishmaniasis: a promising antigen discovery approach of vaccine candidates.
    Kashino SS; Abeijon C; Qin L; Kanunfre KA; Kubrusly FS; Silva FO; Costa DL; Campos D; Costa CH; Raw I; Campos-Neto A
    Parasite Immunol; 2012 Jul; 34(7):360-71. PubMed ID: 22443237
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Leishmaniasis in Turkey: Visceral and cutaneous leishmaniasis caused by Leishmania donovani in Turkey.
    Özbilgin A; Harman M; Karakuş M; Bart A; Töz S; Kurt Ö; Çavuş İ; Polat E; Gündüz C; Van Gool T; Özbel Y
    Acta Trop; 2017 Sep; 173():90-96. PubMed ID: 28587839
    [TBL] [Abstract][Full Text] [Related]  

  • 28. DNA vaccine against visceral leishmaniasis: a promising approach for prevention and control.
    Kumar A; Samant M
    Parasite Immunol; 2016 May; 38(5):273-81. PubMed ID: 27009772
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Nanomedicines for Therapy of Visceral Leishmaniasis.
    Want MY; Yadav P; Afrin F
    J Nanosci Nanotechnol; 2016 Mar; 16(3):2143-51. PubMed ID: 27455613
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Leishmania donovani: immunostimulatory cellular responses of membrane and soluble protein fractions of splenic amastigotes in cured patient and hamsters.
    Kumari S; Misra P; Tandon R; Samant M; Sundar S; Dube A
    PLoS One; 2012; 7(1):e30746. PubMed ID: 22292030
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Visceral leishmaniasis: A novel nuclear envelope protein 'nucleoporins-93 (NUP-93)' from Leishmania donovani prompts macrophage signaling for T-cell activation towards host protective immune response.
    Singh MK; Jamal F; Dubey AK; Shivam P; Kumari S; Pushpanjali ; Bordoloi C; Narayan S; Das VNR; Pandey K; Das P; Singh SK
    Cytokine; 2019 Jan; 113():200-215. PubMed ID: 30001865
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Live Attenuated Leishmania donovani Centrin Knock Out Parasites Generate Non-inferior Protective Immune Response in Aged Mice against Visceral Leishmaniasis.
    Bhattacharya P; Dey R; Dagur PK; Joshi AB; Ismail N; Gannavaram S; Debrabant A; Akue AD; KuKuruga MA; Selvapandiyan A; McCoy JP; Nakhasi HL
    PLoS Negl Trop Dis; 2016 Aug; 10(8):e0004963. PubMed ID: 27580076
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Involvement of CD4⁺ Foxp3⁺ regulatory T cells in persistence of Leishmania donovani in the liver of alymphoplastic aly/aly mice.
    Tiwananthagorn S; Iwabuchi K; Ato M; Sakurai T; Kato H; Katakura K
    PLoS Negl Trop Dis; 2012; 6(8):e1798. PubMed ID: 22928057
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Leishmania donovani: dynamics of L. donovani evasion of innate immune cell attack due to malnutrition in visceral leishmaniasis.
    Kumar V; Bimal S; Singh SK; Chaudhary R; Das S; Lal C; Pandey K; Das VR; Das P
    Nutrition; 2014 Apr; 30(4):449-58. PubMed ID: 24607302
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Antigenicity of
    Fernández L; Carrillo E; Sánchez-Sampedro L; Sánchez C; Ibarra-Meneses AV; Jimenez MA; Almeida VDA; Esteban M; Moreno J
    Front Immunol; 2018; 9():843. PubMed ID: 29740446
    [No Abstract]   [Full Text] [Related]  

  • 36. Heterologous priming-boosting with DNA and vaccinia virus expressing kinetoplastid membrane protein-11 induces potent cellular immune response and confers protection against infection with antimony resistant and sensitive strains of Leishmania (Leishmania) donovani.
    Guha R; Das S; Ghosh J; Naskar K; Mandala A; Sundar S; Dujardin JC; Roy S
    Vaccine; 2013 Apr; 31(15):1905-15. PubMed ID: 23499564
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A new model of progressive visceral leishmaniasis in hamsters by natural transmission via bites of vector sand flies.
    Aslan H; Dey R; Meneses C; Castrovinci P; Jeronimo SM; Oliva G; Fischer L; Duncan RC; Nakhasi HL; Valenzuela JG; Kamhawi S
    J Infect Dis; 2013 Apr; 207(8):1328-38. PubMed ID: 23288926
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Epidemiological aspects of vector, parasite, and domestic reservoir in areas of recent transmission and no reported human cases of visceral leishmaniasis in Brazil.
    Lara-Silva Fde O; Michalsky ÉM; Fortes-Dias CL; Fiuza Vde O; Pessanha JE; Regina-Silva S; de Avelar DM; Silva MA; Lima AC; da Costa AJ; Machado-Coelho GL; Dias ES
    Acta Trop; 2015 Aug; 148():128-36. PubMed ID: 25882769
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A spotlight on the diagnostic methods of a fatal disease Visceral Leishmaniasis.
    Kumar A; Pandey SC; Samant M
    Parasite Immunol; 2020 Oct; 42(10):e12727. PubMed ID: 32378226
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Use of a recombinant cysteine proteinase from Leishmania (Leishmania) infantum chagasi for the Immunotherapy of canine visceral Leishmaniasis.
    Ferreira JH; Silva Ldos S; Longo-Maugéri IM; Katz S; Barbiéri CL
    PLoS Negl Trop Dis; 2014 Mar; 8(3):e2729. PubMed ID: 24625516
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.